非小细胞肺癌化疗患者骨髓抑制发生状况及其影响因素王合法1闫光辉2杨召锋21许昌龙耀医院肿瘤科(许昌461700)2许昌龙耀医院肿瘤内科(许昌461700)【摘要】目的分析非小细胞肺癌化疗患者骨髓抑制发生状况及其影响因素。方法回顾性分析2017年2月—2019年8月期间本院进行化疗治疗的80例非小细胞肺癌患者临床资料,统计非小细胞肺癌化疗患者骨髓抑制发生情况,并根据其情况分组;收集所有患者临床资料,分析非小细胞肺癌化疗患者骨髓抑制发生的相关影响因素。结果80例非小细胞肺癌化疗患者中发生骨髓抑制45例,发生率为56.25%;经单因素及多项Logistic回归分析,年龄≥60岁、化疗方案为紫杉醇联合铂类,TNM分期在Ⅲ-Ⅳ期,发生骨转移是非小细胞肺癌化疗患者发生骨髓抑制的影响因素(OR>1,P<0.05)。结论年龄≥60岁、化疗方案为紫杉醇联合铂类,TNM分期在Ⅲ-Ⅳ期,发生骨转移会增加非小细胞肺癌化疗患者骨髓抑制的发生风险,临床上可据此来制定合理的干预措施,以降低患者骨髓抑制的发生风险。【关键词】非小细胞肺癌;化疗;骨髓抑制DOI:10.3969/j.issn.1000-8535.2023.02.012Occurrenceofbonemarrowsuppressionanditsinfluencingfactorsinpatientswithnon-smallcelllungcancerundergoingchemotherapyWANGHefa1,YANGuanghui2,YANGZhaofeng21DepartmentofOncology,XuchangLongyaoHospital,Xuchang461700,China2DepartmentofOncologyMedicine,XuchangLongyaoHospital,Xuchang461700,China【Abstract】ObjectiveToanalyzetheoccurrenceandinfluencingfactorsofbonemarrowsuppressioninpatientswithnon-smallcelllungcancer(NSCLC)undergoingchemotherapy.MethodsTheclinicaldataof80patientswithNSCLCwhoreceivedchemotherapyinourhospitalfromFebruary2017toAugust2019wereretrospectivelyanalyzed,theoccurrenceofbonemarrowsuppressioninpatientswithNSCLCunderchemotherapywasenrolledandgroupedaccordingtothesituation;theclinicaldataofallpatientswerecollected,therelatedinfluencingfactorsofbonemarrowsuppressioninpatientswereana-lyzed.ResultsAmong80casesofpatientswithNSCLC,45casesoccurredbonemarrowsuppression,theincidencewas56.25%;afterunivariateandmultivariateLogisticregressionanalysis,age≥60yearsold,chemotherapyofpaclitaxelcom-binedwithplatinum,TNMstageinstageIII-IV,theoccurrenceofbonemetastasisweretheinfluencingfactorsofbonemar-...
